Product Details:
Minimum Order Quantity | 1 Stripe |
Dose/Strength | 90 mg |
Packaging Size | 10*30 Tablets |
Packaging Type | Stripe |
Brand | Axcer 90 Mg Tablets |
Manufactured By | sun |
Usage/Application | Personal |
Shelf Life | 3 years |
Product Details:
Minimum Order Quantity | 1 Stripe |
Packaging Type | Stripe |
Brand | Axcer 60 Mg Tablets |
Manufactured By | sun |
Usage/Application | Personal |
Shelf Life | 3 years |
Product Details:
Minimum Order Quantity | 1 Bottle |
Strength | 20 mg |
Packaging Size | 1*10 Tablets |
Manufacturer | sun |
Shelf Life | 3 year |
Storage Instruction | 24-30 |
Usage/Application | Commercial |
Product Details:
Brand Name | Rascase 1.5 Mg Injection |
Brand | sayre |
Manufacturer | sayre |
Dose | 1.5 mg |
Packaging Type | vial |
Medicine Type | Injection |
Usage/Application | Commercial |
Composition | Rasburicase |
Injectable Form | Liquid |
Injection Site | Intramuscular |
Storage | 2-8 |
Product Details:
Minimum Order Quantity | 1 Bottle |
Strength | 250 mg |
USES OF ABIRAPRO TABLET | Prostate cancer |
MARKETER | Glenmark Pharmaceuticals Ltd |
SALT COMPOSITION | Abiraterone Acetate (250mg) |
STORAGE | Store below 30 DegreeC |
Product Details:
Minimum Order Quantity | 1 Stripe |
Dose/Strength | 100 mg |
Packaging Size | 10 Tab |
Packaging Type | Stripe |
Manufacturer | Zydus |
Usage/Application | Personal |
Shelf Life | 36 Months |
Product Details:
Minimum Order Quantity | 1 Vial |
Manufacturer | zydus |
Prescription/Non prescription | Prescription |
Composition | trastuzumab |
Brand | Ujvira 160 mg injection |
Packaging Size | Ujvira 160 mg injection |
Product Name | Ujvira 160 mg injection |
Treatment | anti cancer medicine |
Product Details:
Storage | COLD |
Dosage Form | INJECTION |
Packaging | BOX |
Prescription/Non prescription | Prescription |
Packaging Size | BOX |
Product Details:
Minimum Order Quantity | 1 Vial |
Manufacturer | zydus |
Brand | Leugard 22.5 Depot Injection |
Packaging | vial |
Storage | 2-8 |
Packaging Size | vial |
Composition | leuprolide 11.25 mg |
Prescription/Non prescription | Prescription |
Treatment | To manage endometriosis, relieving pain and reducing endometriotic lesions For preoperative hematolo |
LEUGARD 22.5 DEPOT INJECTION contains Leuprolide which belongs to the group of medicines called Gonadotropin Releasing Hormone (GnRH) Agonist. It is used for palliative treatment (relieving symptoms and minimising the associated suffering) of advanced prostatic cancer.
Advanced prostatic cancer is a cancer (abnormal cell multiplication and differentiation) that originates in the prostate gland and spreads to the other parts of the body. It is characterized by the symptoms such as painful urination, decreased urine pressure, blood in the semen, bone pain, leg swelling, and weakness.
Do not receive LEUGARD 22.5 DEPOT INJECTION if you are allergic to Leuprolide, GnRH, GnRH agonist analogs.
Before receiving this medicine, inform your doctor if you have liver impairment, kidney impairment, congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, metastatic vertebral lesions, urinary tract obstruction, or diabetes.
Before receiving this medicine, inform your doctor if you have a history of seizures, epilepsy, cerebrovascular disorders, or central nervous system anomalies/tumours. LEUGARD 22.5 DEPOT INJECTION is not recommended for use in pregnant women, breastfeeding women, and children.
It should be used with caution in elderly patients (aged above 65 years). Consult your doctor before receiving.
The most common side effects associated with the use of LEUGARD 22.5 DEPOT INJECTION are general pain, reactions at the site of injection, hot flashes/sweating, gastrointestinal disorders, joint disorders, shrinking of testes, urinary disorders, infections in upper respiratory tract, and fatigue. Consult your doctor if any of these side effects worsens.
USES OF LEUGARD 22.5 DEPOT INJECTIONLEUGARD 22.5 DEPOT INJECTION helps in palliative treatment of advanced prostatic cancer where leuprolide works by blocking the secretion of gonadotropin releasing hormone (GnRH) following an initial stimulation, resulting in suppression of ovarian and testicular steroidogenesis (process of synthesis of steroid hormones), thereby relieving the symptoms associated with increased testosterone levels in advanced prostatic cancer.
DIRECTIONS FOR USEFor intramuscular use:
LEUGARD 22.5 DEPOT INJECTION will be administered to you only by a doctor or a nurse intramuscularly (into the muscle) or subcutaneously (under the skin). Your doctor will administer the correct dose and duration for you depending upon your age, body weight and disease condition.
SIDE EFFECTS OF LEUGARD 22.5 DEPOT INJECTIONCOMMON